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Abstract
Background: Since 2000, the Global Alliance for Vaccines and Immunization (GAVI) and WHO have supported the
introduction of the Pneumococcal Conjugate Vaccine (PCV) in the immunization programs of developing countries.
The highest pneumococcal nasopharyngeal carriage rates have been reported (40-60%) in these countries, and the
highest incidence and case fatality rates of pneumococcal infections have been demonstrated in Africa.
Methods: Studies concerning nasopharyngeal pneumococcal carriage and pneumococcal infection in children less
than 5 years old were conducted in Dakar from 2007 to 2008. Serotype, antibiotic susceptibility and minimum
inhibitory concentrations were determined. In addition, among 17 overall publications, 6 manuscripts of the
Senegalese literature published from 1972 to 2013 were selected for data comparisons.
Results: Among the 264 children observed, 132 (50%) children generated a nasopharyngeal (NP) positive culture
with Streptococcus pneumoniae. The five most prevalent serotypes, were 6B (9%), 19 F (9%), 23 F (7.6%), 14 (7.6%)
and 6A (6.8%). Fifteen percent of the strains (20/132) showed reduced susceptibility to penicillin and 3% (4/132)
showed reduced susceptibility to anti-pneumococcal fluoroquinolones. Among the 196 suspected pneumococcal
infections, 62 (31.6%) Streptococcus pneumoniae were isolated. Serogroup 1 was the most prevalent serotype
(21.3%), followed by 6B (14.9%), 23 F (14.9%) and 5 (8.5%). Vaccine coverage for PCV-7, PCV-10 and PCV-13, were
36.2% (17/47), 66% (31/47) and 70.2% (33/47) respectively. Reduced susceptibility to penicillin and anti-
pneumococcal fluoroquinolones was 6.4% and 4.3%, respectively, and the overall lethality was 42.4% (14/33).
Conclusions: This study confirms a high rate of carriage and disease caused by Streptococcus pneumoniae
serotypes contained within the current generation of pneumococcal conjugate vaccines and consistent with
reports from other countries in sub-Saharan Africa prior to PCV introduction. Antimicrobial resistance in this small
unselected sample confirms a low rate of antibiotic resistance. Case-fatality is high. Introduction of a high valency
pneumococcal vaccine should be a priority for health planners with the establishment of an effective surveillance
system to monitor post vaccine changes.
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Background
In developed nations, a substantial decrease in the inva-
sive pneumococcal disease (IPD) incidence rate has
been achieved through the introduction of the 7-valent-
pneumococcal conjugated vaccine (PCV-7) into pediatric
immunization programs. PCV-10 and PCV-13 including
additional pneumococcus serotypes are now gradually re-
placing PCV-7 in immunization programs mainly in de-
veloped countries [1,2] but also in developing countries
[3,4]. In contrast, the incidence of IPD has changed little
in developing countries (DC), reflecting poor access to
pneumococcal vaccination and the fact that PCV-7 does
not contain serotypes 1, 5 and 6A known to be prevalent
in Africa [5]. Nevertheless, the funding received from the
Global Alliance for Vaccines and Immunization (GAVI)
since 2000 and WHO recommendations for PCV use since
2007 [6] have increased the introduction of PCV in national
immunization programs. In December 2012, the PCV
introduction among WHO member states reached 41%
(19/46) in Africa [6], and both Gambia [7,8] and Kenya
[3,4] are currently evaluating the national impact of PCV
initiatives on carriage prevalence and serotype distribution.
Most Streptococcus pneumoniae (S. pneumoniae) sero-
types colonize the nasopharyngeal niche as commensal in-
habitants and subsequently migrate to cause IPD [9]. The
most commonly observed serotypes in nasopharyngeal
(NP) carriage worldwide, 6B, 19 F, and 23 F, are less inva-
sive, but are also more likely to harbor antibiotic resistance
[5], whereas serotypes 5, 7 F, and 1 are infrequent colo-
nizers that are more invasive, especially in Africa [10].
Young children in DC, where overcrowding is typical, are
risk groups for this dissemination, showing the highest
carriage rates worldwide (40-60%) [5,11].
Since 2000, the pneumococcal infection burden in Africa
has been a source of great concern, as this continent has
the highest incidence of pneumococcal infections (3627 per
100000) and pneumococcal mortality (399 per 100000),
with case fatality rates of 11%, 73% and 58% for pneu-
monia, meningitis and non-pneumonia non-meningitis
diseases, respectively [12].
In West African countries, serotype 1 is the most preva-
lent serotype in IPD, followed by serogroups 5, 6, 2, 3 and
12 [13]; however, this serogroup distribution might be dif-
ferent according to the country, therefore the serotype
coverage in this region varies. For example, the serotype
coverage ranges from 39% to 80% for PCV10 [14]. In
countries where pneumococcal vaccination has been initi-
ated, the surveillance of pneumococcal isolates remains a
necessity with regard to pneumococcal carriage and dis-
ease, antibiotic resistance prevalence rate, capsular switch-
ing and vaccine escape [10].
The prevalence of Penicillin Non-Susceptible Pneumo-
coccus (PNSP) has increased worldwide, associated with
the spread of specific clones with serotypes 6B, 9 V, 14,
19 F, and 23 F. After the introduction of PCV-7 a reduc-
tion in antibiotic-resistant infections has been observed,
reflecting a decline in the incidence of IPD caused by
PCV-7 serotypes. To go beyond the disease protection
capacity of PCV-7, extended valency vaccines have been
developed which include 3 and 6 additional capsular
polysaccharides (1, 3, 5, 6A, 7 F and 19A). These PCVs
designated PCV-10 and PCV-13 are gradually used and
licensed in many countries around the world. These
implementations provide the opportunity to more deeply
investigate the impact these vaccines will have on disease
[1,15].
In the present study, we performed a PubMed search
for studies on S. pneumoniae infection and NP carriage
in Senegal published from January 1, 1972 to September
30, 2013 and selected pediatric studies for comparison
with our current findings. Herein, we report the serotype
distribution and antibiotic resistance of S. pneumoniae
isolated from NP carriage and IPD patients, and these
data were compared with previous data from studies
conducted in Senegal. Moreover, the question of the
most appropriate PCV for Senegal is discussed regarding




This study was approved through the Ethics Committee
of the Ministry of Health. Written consent was obtained
from parents or legal guardians before inclusion. A de-
tailed description of the study was provided in the native
language for illiterate individuals and for both studies
different questionnaires were conducted.
Population study
This study was conducted in Dakar, the capital of Senegal,
in 2007 and 2008. All samples were collected from children
less than five years of age. Experiments involving pneumo-
coccal carriage were conducted at 2 Health Centers located
in Medina and Saint Martin in Dakar between March 2007
and October 2008. These two Health Centers have been
chosen for their localization in popular areas and their cap-
acities to draw a large population of children from sur-
rounding areas. Medical activities comprise primary care,
vaccinations, medical consultations and hospitalizations.
Children consulting for vaccination were asked to pro-
vide a nasopharyngeal swab sample (Calgiswab, VWR).
During the 20 month period of the study, in both Health
Centers, children were sampled on nine different months
over the study period, two days per month, on a total of
18 days. Children were sampled once and very few refusals
were recorded. Exclusion criteria were presence of anti-
biotic consumption within the preceding 2 weeks.
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In the clinical study, during 21 months, from January
2007 to September 2008, children with suspected S.
pneumoniae disease were recruited in the pediatric
wards from the Albert Royer/Fann University Hospital.
The Albert Royer hospital is the referral pediatric center
in Dakar and children attending these pediatric units
originate from the city of Dakar and its outskirts, but
also from more remote areas outside the capital.
An IPD case was defined as culture of S. pneumoniae
from a normally sterile body site as blood, CSF or
pleural effusion. The diagnosis of meningitis was based
on S. pneumoniae identified in CSF through culture.
Septicemia was defined as S. pneumoniae cultured in
blood with no distinctive clinical syndrome. The diagno-
sis of empyema was based on cultures positive for S.
pneumoniae that were taken from pleural fluids. Repeat
samples from sterile sites from the same child were
regarded as part of the same episode and one isolate was
included if both isolates expressed the same serotype.
Specimens were sampled in accordance with the clinical
pattern; here are reported results of blood-cultures, CSF,
and pleural fluids.
Laboratory experiments
The Albert Royer hospital medical laboratory processed
the bacterial cultures of all the specimens sampled from
hospitalized children. S. pneumoniae isolates were then
sent to the Pasteur Institute laboratory for susceptibility
testing and serotyping. S. pneumoniae was isolated and
identified using common bacteriological methods. The sus-
pected samples were streaked onto fresh sheep blood agar
plates (5%) containing optochin disks and incubated at 35-
37°C with 5% CO2 for 24 h; in cases of negativity, the
cultures were incubated up to 48 h. Bacteria showing
inhibition zones around the optochin disks were subjected
to additional tests, such as gram staining, catalase reaction
and latex agglutination (Slidex Pneumo-Kit®, bioMérieux).
The capsular type was determined for 23 different ser-
ogroups through latex agglutination (Pneumotest kit,
Statens Serum Institute, Copenhagen Denmark). Then
when needed, traditional factor antisera were used to sero-
typing the PCV-7 serogroups 6, 9, 18, 19 and 23 by the
Quellung reaction. The isolates showing no reactivity were
defined as “Non Typed” (NT) strains. Beta-lactam (BL) and
Fluoroquinolone (FQ) susceptibility was examined using
the disk-diffusion method according to the Comité de
l’Antibiogramme de la Société Française de Microbiologie
(CASFM 2008, http://www.sfm-microbiologie.org). CASFM
and EUCAST (European Committee on Antimicrobial
Susceptibility Testing, http://eucast.org) guidelines recom-
mend the use of different oxacillin disk screening tests for
detection of penicillin resistant pneumococci, a 5-μg oxacil-
lin disk for CASFM and a 1-μg oxacillin disk for EUCAST.
As a result, cut-off values of the inhibition zone are 26 mm
and 20 mm, respectively. In cases of intermediate or resist-
ant susceptibility, the Minimum Inhibitory Concentration
(MIC) was determined for BL and FQ using a standard agar
diffusion method (Steer’s multipoint apparatus). The Steer’s
device is an inoculum replicator with multipoints delivering
simultaneously up to 96 dots of the prepared bacterial
suspension on the surface of the agar plates [16].
Senegalese literature
From January 1, 1972 to September 30, 2013, 17 publica-
tions on pneumococcal infections in Dakar were retrieved
from PubMed using S. pneumoniae, infection, nasopha-
ryngeal carriage, Dakar, Senegal, and Africa as keywords.
Six of the 17 publications including available results con-
cerning children less than 5 years of age, 4 in French and
2 in English, were selected for further analysis.
Statistical analysis
Proportions were calculated with 95% Confidence Inter-
val [CI] when relevant. Mean age values and sex ratios
were estimated on children from both the carriage and
the invasive disease studies.
Results
Nasopharyngeal carriage study
The Nasopharyngeal (NP) carriage study included 264
children less than 24 month of age; 253 (95.8%) children
were between 0 and 12 month of age, and the mean age
was 5 months, with a sex ratio (M/F) of 1.13. Among
the 264 children, 132 (50%; 95% CI, 44-56%) children
had NP positive S. pneumoniae cultures. S. pneumoniae
NP positive carriers were observed as early as the first
month after delivery. The serotype distribution displayed
28 different serotypes. The five most prevalent serotypes
were 19 F (9%, 12/132), 6B (9%, 12/132), 14 (7.6%, 10/
132), 23 F (7.6%, 10/132), and 6A (6.8%, 9/132), account-
ing for 40.2% of the overall serotypes (Figure 1). Sero-
type 1 was detected in 2 of the 132 children. PCV-7
covered 48/132 (36.4%), PCV-10 covered 52/132 (39.4%)
and PCV13 covered 70/132 (53%) of the identified
serotypes (Figure 2).
According to CASFM, among the 132 isolates, 70
showed an inhibition diameter of less than 26 mm on the
oxacillin disk (5 μg), 20 (15%; 95% CI, 9-22%) of the iso-
lates showed reduced susceptibility to penicillin by MIC
determination (MIC ≥ 0.12 mg/L) and 2 of the 20 isolates
were resistant to penicillin (>2 mg/L). The first strain, of
NT serotype (penicillin MIC = 4 mg/L), was also amoxicil-
lin resistant (MIC = 4 mg/L) and cefotaxime non-
susceptible (MIC = 1 mg/L), and the second strain, of 23 F
serotype (penicillin MIC = 8 mg/L), was amoxicillin and
cefotaxime susceptible. The mean value of penicillin MIC
among the 20 PNSP was 0.33 mg/L. Regarding FQ resist-
ance among the 132 isolates, 32 S. pneumoniae isolates
Ba et al. BMC Infectious Diseases 2014, 14:627 Page 3 of 8
http://www.biomedcentral.com/1471-2334/14/627
showed a reduced susceptibility to ciprofloxacin, of which
10 isolates (7.6%, 10/132) were completely resistant to this
antibiotic (MICs 4 to 8 mg/L), while 3 isolates were levo-
floxacin resistant (MIC = 4, 4 and 64 mg/L) and 1 isolate
was moxifloxacin resistant (MIC = 1 mg/L).
Invasive pneumococcal disease study
During the 21 month IPD study, 196 children between 0
and 5 years of age were included; the mean age was
15.5 months, with 54.6% (107/196) of the children less
than 1 year old, and the sex ratio (M/F) was 1.3.Two hun-
dred and forty specimens were collected, 144 blood-
streams, 75 CSF and 21 pleural fluid (PF) samples. Among
101 children with blood samples, 74 children with CSF
samples and 21 children with PF samples, 12 septicemia
cases (12/101, 11.9%), 42 meningitis cases (42/74, 56.8%)
and 8 empyema cases (8/21, 38%) were observed. Sixty
two S. pneumoniae infected children out of the 196 sus-
pected children were finally included (31.6%).
Antibiotic susceptibility testing and isolate serotyping
were performed on 47 (75.8%) of the 62 S. pneumoniae iso-
lates: 29 meningitis cases, 10 septicemia cases and 8 empy-
ema cases. Twenty different serotypes were identified
(Figure 3). Serotype 1 was the most prevalent serotype
(10/47, 21.3%; 95% CI, 9-33%), followed by 6B (14.9%, 7/47)
and 23 F (14.9%, 7/47) and 5 (8.5%, 4/47).
Among the 29 S. pneumoniae meningitis, 16 different
serotypes were identified, and serotypes 1 (6/29, 20.7%;
95% CI, 5-36%), was the most prevalent followed by 23 F
(4/29, 13.8%) and 6B (3/29, 10.3%) (Figure 3).
The mean vaccine coverage was 36.2% (17/47) with
PCV-7, 66% (31/47) with PCV-10 and 70.2% (33/47)
with PCV-13 (Figure 2). The meningitis vaccine cover-
age was 31% (9/29) with PCV-7, 55.2% (16/29) with
PCV-10 and 58.6% (17/29) with PCV-13 (Figure 2).
Three isolates showed reduced susceptibility to peni-
cillin, and these bacteria were isolated from meningitis
cases. Among the 3 PNSPs, one isolate was resistant to
penicillin (MIC = 16 mg/L), amoxicillin (MIC = 32 mg/
L) and cefotaxime (MIC = 32 mg/L). Among the 17
isolates with reduced susceptibility to ciprofloxacin
(36.2%; MIC > 0.12 mg/L), 2 isolates were moxifloxacin
(MIC = 4 and 16 mg/L) and levofloxacin resistant (MIC
= 32 mg/L). The isolate simultaneously resistant to BL
and FQ was of serotype 1, and the second FQ resistant
isolate was of serotype 5.
The outcomes were known for 33 children out of the 62
children (53.2%) and 22 children out of the 42 meningitis
cases with S. pneumoniae positive results, showing an
overall lethality of 42.4% (95% CI, 25-60%) (14/33) and a
meningitis lethality of 54.5% (95% CI, 32-76%) (12/22).
Regarding the 6 Senegalese publications, one study con-





















Figure 1 Serotype distribution of S. pneumoniae isolates from NP carriage in children ≤24 months of age attending 2 health care
centers in Dakar, Senegal. The serotypes are listed on the X-axis, starting with the NT, and followed by the serotypes covered by PCV-7, PCV-10






















NP Carriage                                                       IPD                                                       Meningitis
Figure 2 PCV-7, PCV-10 and PCV-13 vaccine coverage in S. pneumoniae NP carriage, IPD and meningitis. PCVs are listed on X-axis by NP
carriage, IPD and Meningitis. 95% Confidence Intervals are shown for each PCV vaccine coverage.
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(RTI) [17], one study focused on NP carriage [18] and four
studies concerned meningitis and invasive infections
[19-22]. The serotype results were available in one NP car-
riage study, and susceptibility testing and lethality were
assessed in 3 studies.
Discussion
Carriage
The 50% (132/264) mean NP carriage prevalence rate
observed in the present study is consistent with the re-
sults obtained in most of the publications concerning
young children [5,15]; indeed, Echave et al. in 2003 [17]
reported a prevalence rate of 56% in Senegal. However,
Baylet et al. reported higher NP carriage prevalence rates
in rural (77%) and urban (69.6%) areas [18] in Senegal
and other African countries. In Kenya, the NP carriage
was 65.8% in children less than 5 years old and 79% in
children 6–11 months of age [23]. In Nigeria, infants less
than 2 years showed NP prevalence rates of 74.4%, with
a peak value between 6–9 months [24], and in Burkina
Faso [25], the NP carriage rate was 69.4% in children less
than 1 year of age versus the 48% carriage rate observed
in the present study.
The high NT prevalence rate observed in our study is
partially due to the Pneumotest-kit used for serotype deter-
mination in the laboratory, with only 23 different ser-
ogroups identified. This corresponds to non-typed strains
rather than to non-typable strains. The most prevalent
carriage serotypes found in this study were 6B, 19 F, 23 F,
14, 6A, 11 and 19A (Figure 1), and some (6B, 23 F) of these
serotypes were concurrently observed in IPD (Figure 3).
This serotype distribution (19 F, 6B, 6A, 23 F), is similar to
that reported in Ghana [26], Kenya [23] and Nigeria [24].
The determination of serotype coverage showed, a
similar Senegalese PCV-13 coverage (53%, 95% CI, 45-
61%, 70/132) to other African countries, such as Ghana
(50%) [26], Kenya (59%) [23], and Nigeria (61.7%) [24].
In Senegal, the 15% PNSP prevalence rate observed in
the present study, with a high proportion of intermediate
resistance (90%), is consistent with the results of the
Echave et al. study conducted in a Senegalese rural area
in 2003 (13%) [17]. However, at that time, MIC testing
on PNSP was not performed, and the 13% prevalence
rate could actually be lower than reported. In Nigeria
and in Ghana, rare penicillin-resistance isolates were de-
tected but rather an intermediate resistance to this anti-
biotic was observed, 30.9% and 45% respectively [24,26].
In Senegal, the prevalence of anti-pneumococcal FQ re-
sistance (moxifloxacin and levofloxacin) was 3% (4/132),
with a serotype 11 isolate showing a high levofloxacin
MIC (64 mg/L). These results suggest that S. pneumo-
niae antibiotic resistance in NP carriage is not a major
concern in Senegal.
IPD
Our study has limitations due to single hospital site re-
cruitment; however we believe that our surveillance cap-
tures most laboratory-confirmed IPD cases and, because
pediatric wards in the Albert Royer hospital welcome a
large population of children living in the Dakar region,
enables comparison with other published data from
Senegal or other African countries.
The study is also limited by the incomplete serotyping
and susceptibility testing of overall cultured isolates. Given
these limitations, results have to be discussed cautiously,
but in case more isolates had been tested, we are unlikely
to see contradictory findings as these data are consistent
with previous Senegalese and sub-Saharan Africa published
results.
The most prevalent serotypes were serotype 1 (21.3%),
6B (14.9%), 23 F (14.9%) and 5 (8.5%) in accordance with
what is known in Africa [14] (Figure 3). Dia et al. reviewed
103 isolates from invasive and non-invasive diseases col-
lected in Senegal during 2 distinct periods (1996–1999
and 2007–2010) and reported findings similar to those of
the present study, with 1, 23 F, 5 and 6B as the most fre-
quent serotypes in IPD [22]. In West African countries,
























Figure 3 Serotype distribution by IPD and meningitis in children ≤5 years of age attending pediatric units in Albert Royer hospital in
Dakar, Senegal. The serotypes are listed on the X-axis, starting with the NT, and followed by the serotypes covered by PCV-7, PCV-10 and
PCV-13. The NVT are listed consecutively from serotype 15 to serotype 18 F.
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age are 5, 6A, 1 and 14, and in Burkina Faso and Senegal
the three most prevalent serotypes are 1, 5 and 6 [14].
The vaccine coverage observed in the present study
(Figure 2) is consistent with the results of Donkor et al.,
reporting West African serotype coverage of 2%–36% for
PCV7, 39%–80% for PCV10, and 65%–87% for PCV13
[14].
Among the 29 S. pneumoniae meningitis tested with
28 different antisera, 16 different serotypes were identified,
and serotypes 1 (6/29, 20.7%; 95% CI, 5-36%), was the
most prevalent followed by 23 F (4/29, 13.8%), and 6B (3/
29, 10.3%) (Figure 3). Serotype data have been obtained in
3 previous studies on meningitis in Senegal [19-21]. In the
70s the most frequent serotypes were 5, 6, 23 and 12, al-
though serotype 1 was also detected (4-8%). Dia et al. re-
ported similar results to the present study, with serotype 1
as the leading serotype in meningitis between 2006 and
2010, followed by 23 F, 5, and 6B. Differences between the
serotype distribution reported in the 70s and the current
findings involve serotypes 1 and 5, as the prevalence of
these bacteria has changed with time. Interestingly, the
meningitis serotype coverage has not changed since the
70s [20] (Figure 4); however, at this time the serotypes were
only examined at the serogroup level, potentially resulting
in an overestimation of the vaccine coverage rate. Meningi-
tis serotype coverage rates for PCV-10 and PCV-13 are
55.2% (95% CI, 36-74%) and 58.6% (95% CI, 40-77%), re-
spectively, and these values are similar to the meningitis
vaccine coverage rate reported in the Togo and the Burkina
Faso for PCV-10 and 13 (53%) [27].
In our study, 4 PNSPs were isolated from 53 IPD cases,
the PNSP prevalence rate is 7.5% (95% CI, 0-15%). In 2003,
Echave et al. reported an 18% PNSP prevalence rate in
RTI, with no MIC determination to distinguish penicillin
intermediate and resistant isolates in Senegal [17]. Dia
et al. [22] did not report any information concerning
PNSPs. A meta-analysis was conducted in 2013 to examine
the antibiotic susceptibility of community acquired invasive
infections from 1978 to 2011 in Africa [28]. This publica-
tion reports antibiotic resistance rates in IPD of 19.3% to
penicillin, 8.6% to amoxicillin, and 0.9% to ceftriaxone and
concluded that the majority of pneumococci remains sus-
ceptible to amoxicillin. Regarding beta-lactamin antibiotic
resistances in Senegal the situation is similar to these find-
ings conversely to Ethiopia where resistance rates were
31.3%, 29% and 9.8% for penicillin, ampicillin and ceftriax-
one respectively [29]. Anti-pneumococcal FQ resistance
rates (levofloxacin and moxifloxacin) remain moderate for
levofloxacin (2/53, 3.8%; 95% CI, 0-9%), but could be
higher for moxifloxacin (5/53, 9.4%; 95% CI, 1-18%).
Therefore PNSPs are not widespread in Senegal, but
serotype 1 isolates with high MIC to BL, associated with
FQ resistance are present and emergence of such isolate
would be concerning.
Even though outcomes were only known for 53.2%
(33/62) of children with S. pneumoniae positive results,
the high overall case fatality rate (CFR) (44%; 95% CI,
27-61%) and meningitis CFR (54.5%;95% CI, 32-76%)
found are consistent with lethality reported in other African
countries, with a mean rate of 73% (18%-94%) in meningitis
[12]. These CFR are also similar to the results of studies
conducted in the 70s in Senegal [20], and this lack of
improvement represents a major concern.
Since November 2012, the introduction of PCV-7 has
been recommended in Senegal, administered at two
doses at 2 and 3 months of life, generating a family cost
of 109.2 USD per dose. The invasiveness of individual
serotypes is reflected in the case:carrier ratio (CCR)























Figure 4 Meningitis serotype coverage comparisons between 1970–1979 and 2007–2008. PCVs are listed on the X-axis. 95% Confidence
Intervals for serotype coverage are shown for the 2007–2008 period.
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which distinguish the more from the less invasive sero-
types [30]. Our study with a low number of serotyped
isolates identified, did not fulfill standards allowing CCR
assessment. However, PCV-10 additional types (1, 5, 7 F)
are considered as having higher CCR than the additional
three in PCV-13 (3, 6A, 19A) [31] and our findings
could be in agreement with these statements. Indeed, in
Dakar, PCV-10 additional types comprise 29.8% (14/47)
of IPD isolates but only 1.5% (2/132) of carried isolates
and PCV-13 additional valency vaccines comprise 4.2%
(2/47) of IPD isolates and 13.6% (18/132) of NP carriage
isolates. This observation suggests that in Senegal, PCV-
10 or PCV-13 introduction could reduce the incidence
of IPD, and additional PCV-13 serotypes (3, 6A, and
19A) might have a greater impact on serotype distribu-
tion in carriage than on the reduction of IPD. Regarding
the invasiveness of serotypes and the cost effectiveness,
PCV-7 could be replaced by PCV-10 instead of PCV-13.
Conclusions
Although cefotaxime- and FQ-resistant isolates have been
detected in Senegal, pneumococcal antibiotic resistance is
not a major issue. The primary concern is the CFR, and
measures should be urgently implemented in Pediatric
wards in Dakar to improve children outcomes. An effect-
ive pneumococcal surveillance network should be devel-
oped to collect representative data on pneumococcal
carriage and infection and to detect serotype changes.
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